Literature DB >> 15837551

The pathophysiologic basis for blocking the renin-angiotensin system in hypertensive patients with renal disease.

Leopoldo Raij1.   

Abstract

The current understanding of the interrelationships among hemodynamic, hormonal, and metabolic factors in the pathophysiology of renal disease remains incomplete. In the kidney, the renin-angiotensin system (RAS) plays an important role in all three of these physiologic pathways. There is no doubt that hypertension and diabetes are major risk factors for the progression of renal disease and that interruption of the RAS is renoprotective. In particular, the balance of interactions between angiotensin II and nitric oxide is a key factor in determining whether injury or protection of target organs ensues. Experimental studies suggest a novel link between hemodynamic and metabolic factors that may cooperate to induce progressive glomerular injury in conditions characterized by glomerular hypertension. Emerging data from experimental and clinical studies may lead to improvements in therapeutic efforts to prevent or slow the progression of renal disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15837551     DOI: 10.1016/j.amjhyper.2004.11.040

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  9 in total

1.  Murine recombinant angiotensin-converting enzyme 2: effect on angiotensin II-dependent hypertension and distinctive angiotensin-converting enzyme 2 inhibitor characteristics on rodent and human angiotensin-converting enzyme 2.

Authors:  Minghao Ye; Jan Wysocki; Francisco R Gonzalez-Pacheco; Mahmoud Salem; Karla Evora; Laura Garcia-Halpin; Marko Poglitsch; Manfred Schuster; Daniel Batlle
Journal:  Hypertension       Date:  2012-07-09       Impact factor: 10.190

2.  Angiotensin-converting enzyme 2 amplification limited to the circulation does not protect mice from development of diabetic nephropathy.

Authors:  Jan Wysocki; Minghao Ye; Ahmed M Khattab; Agnes Fogo; Aline Martin; Nicolae Valentin David; Yashpal Kanwar; Mark Osborn; Daniel Batlle
Journal:  Kidney Int       Date:  2016-12-04       Impact factor: 10.612

3.  Angiotensin-converting enzyme 2-independent action of presumed angiotensin-converting enzyme 2 activators: studies in vivo, ex vivo, and in vitro.

Authors:  Philipp K Haber; Minghao Ye; Jan Wysocki; Christoph Maier; Syed K Haque; Daniel Batlle
Journal:  Hypertension       Date:  2014-01-20       Impact factor: 10.190

Review 4.  Optimal therapy in hypertensive subjects with diabetes mellitus.

Authors:  Gianpaolo Reboldi; Giorgio Gentile; Fabio Angeli; Paolo Verdecchia
Journal:  Curr Atheroscler Rep       Date:  2011-04       Impact factor: 5.113

5.  Plasma and Kidney Angiotensin Peptides: Importance of the Aminopeptidase A/Angiotensin III Axis.

Authors:  Jan Wysocki; Minghao Ye; Daniel Batlle
Journal:  Am J Hypertens       Date:  2015-05-11       Impact factor: 2.689

Review 6.  The link between Glut-1 and hypertension in diabetic nephropathy.

Authors:  Luigi Gnudi; Leopoldo Raij
Journal:  Curr Hypertens Rep       Date:  2006-04       Impact factor: 5.369

7.  Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension.

Authors:  Jan Wysocki; Minghao Ye; Eva Rodriguez; Francisco R González-Pacheco; Clara Barrios; Karla Evora; Manfred Schuster; Hans Loibner; K Bridget Brosnihan; Carlos M Ferrario; Josef M Penninger; Daniel Batlle
Journal:  Hypertension       Date:  2009-11-30       Impact factor: 10.190

8.  Reduced plasma ACE2 activity in dialysis patients: another piece in the conundrum of factors involved in hypertension and cardiovascular morbidity?

Authors:  Jan Wysocki; Daniel Batlle
Journal:  Nephrol Dial Transplant       Date:  2013-06-19       Impact factor: 5.992

9.  Renoprotection Provided by Additional Diuretic Treatment in Partially Nephrectomized Ren-2 Transgenic Rats Subjected to the Combined RAS and ETA Blockade.

Authors:  Ivana Vaněčková; Silvie Hojná; Zdenka Vernerová; Michaela Kadlecová; Hana Rauchová; Elzbieta Kompanowska-Jezierska; Zdeňka Vaňourková; Luděk Červenka; Josef Zicha
Journal:  Front Physiol       Date:  2019-09-18       Impact factor: 4.566

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.